Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA trial of pasireotide LAR and everolimus in lung and thymic neuroendocrine tumors
NL-OMON40411Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Bronchopulmonary Carcinoid (BPC) and thymic neuroendocrine carcinoma (TNEC) comparing Pasireotide LAR, Everolimus and Pasireotide LAR + everolimus (3 arms). Primary endpoint: Proportion progression-free at 9 months. Started Nov 2013; status: active, not recruiting.
02
Drugs
pasireotide LAReverolimus
03
Conditions
Bronchopulmonary Carcinoid (BPC)thymic neuroendocrine carcinoma (TNEC)
Beyond the preview
Go deeper on NL-OMON40411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40411.